User login
Key clinical point: Acquired genomic alterations (Acq-Gas) associated with epidermal growth factor receptor (EGFR)-resistance in later lines were rare with first-line anti-EGFR-antibody combined with highly active chemotherapy and comparable with non-anti-EGFR regimen.
Major finding: On progression, ≥1 Acq-GA of interest developed in 6.6% of patients on anti-EGFR-chemotherapy compared with 10.1% of patients on anti-vascular endothelial growth factor (VEGF)-chemotherapy (odds ratio [OR] 0.62; 95% CI 0.20-2.11) and 62.0% of patients on anti-EGFR-antibody therapy in later lines (OR 0.09; 95% CI 0.03-0.23).
Study details: This was a post hoc analysis of the CALGB/SWOG-80405 trial including patients with mCRC who progressed on first-line cetuximab (anti-EGFR)-chemotherapy or bevacizumab (anti-VEGF)-chemotherapy and had pretreatment and post-progression plasma samples available for circulating tumor DNA testing.
Disclosures: This study was supported by the National Cancer Institute of the US National Institutes of Health. Some authors declared receiving honoraria or research funding from, having consulting or advisory roles or stock or other ownership interests in, or serving on speakers’ bureau for various sources.
Source: Raghav K et al. Acquired genomic alterations on first-line chemotherapy with cetuximab in advanced colorectal cancer: Circulating tumor DNA analysis of the CALGB/SWOG-80405 trial (Alliance). J Clin Oncol. 2022 (Sep 6). Doi: 10.1200/JCO.22.00365
Key clinical point: Acquired genomic alterations (Acq-Gas) associated with epidermal growth factor receptor (EGFR)-resistance in later lines were rare with first-line anti-EGFR-antibody combined with highly active chemotherapy and comparable with non-anti-EGFR regimen.
Major finding: On progression, ≥1 Acq-GA of interest developed in 6.6% of patients on anti-EGFR-chemotherapy compared with 10.1% of patients on anti-vascular endothelial growth factor (VEGF)-chemotherapy (odds ratio [OR] 0.62; 95% CI 0.20-2.11) and 62.0% of patients on anti-EGFR-antibody therapy in later lines (OR 0.09; 95% CI 0.03-0.23).
Study details: This was a post hoc analysis of the CALGB/SWOG-80405 trial including patients with mCRC who progressed on first-line cetuximab (anti-EGFR)-chemotherapy or bevacizumab (anti-VEGF)-chemotherapy and had pretreatment and post-progression plasma samples available for circulating tumor DNA testing.
Disclosures: This study was supported by the National Cancer Institute of the US National Institutes of Health. Some authors declared receiving honoraria or research funding from, having consulting or advisory roles or stock or other ownership interests in, or serving on speakers’ bureau for various sources.
Source: Raghav K et al. Acquired genomic alterations on first-line chemotherapy with cetuximab in advanced colorectal cancer: Circulating tumor DNA analysis of the CALGB/SWOG-80405 trial (Alliance). J Clin Oncol. 2022 (Sep 6). Doi: 10.1200/JCO.22.00365
Key clinical point: Acquired genomic alterations (Acq-Gas) associated with epidermal growth factor receptor (EGFR)-resistance in later lines were rare with first-line anti-EGFR-antibody combined with highly active chemotherapy and comparable with non-anti-EGFR regimen.
Major finding: On progression, ≥1 Acq-GA of interest developed in 6.6% of patients on anti-EGFR-chemotherapy compared with 10.1% of patients on anti-vascular endothelial growth factor (VEGF)-chemotherapy (odds ratio [OR] 0.62; 95% CI 0.20-2.11) and 62.0% of patients on anti-EGFR-antibody therapy in later lines (OR 0.09; 95% CI 0.03-0.23).
Study details: This was a post hoc analysis of the CALGB/SWOG-80405 trial including patients with mCRC who progressed on first-line cetuximab (anti-EGFR)-chemotherapy or bevacizumab (anti-VEGF)-chemotherapy and had pretreatment and post-progression plasma samples available for circulating tumor DNA testing.
Disclosures: This study was supported by the National Cancer Institute of the US National Institutes of Health. Some authors declared receiving honoraria or research funding from, having consulting or advisory roles or stock or other ownership interests in, or serving on speakers’ bureau for various sources.
Source: Raghav K et al. Acquired genomic alterations on first-line chemotherapy with cetuximab in advanced colorectal cancer: Circulating tumor DNA analysis of the CALGB/SWOG-80405 trial (Alliance). J Clin Oncol. 2022 (Sep 6). Doi: 10.1200/JCO.22.00365